Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.

Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.

To explore the activity and safety of two schedules of ixabepilone, as first line chemotherapy, in patients with metastatic breast cancer previously treated with adjuvant chemotherapy, a randomized non-comparative phase II study was conducted. From November 2008 until December 2010, 64 patients were...

Full description

Bibliographic Details
Main Authors: George Fountzilas, Vassiliki Kotoula, Dimitrios Pectasides, George Kouvatseas, Eleni Timotheadou, Mattheos Bobos, Xanthipi Mavropoulou, Christos Papadimitriou, Eleni Vrettou, Georgia Raptou, Angelos Koutras, Evangelia Razis, Dimitrios Bafaloukos, Epaminontas Samantas, George Pentheroudakis, Dimosthenis V Skarlos
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3720651?pdf=render

Internet

http://europepmc.org/articles/PMC3720651?pdf=render

Similar Items